Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Race Against Time? One Man’s Search For Artificial Intelligence Medical Device Standards That Can Keep Up

Executive Summary

Pat Baird – Philips Healthcare’s regulatory standards guru – says by the time artificial intelligence/machine learning standards are developed and recognized by regulators, they may already be out-of-date. To speed up the process, he’s taken it upon himself to aggregate the most critical standards to help industry and regulators alike develop guidelines on how such products should be developed and operate.

You may also be interested in...



A Brave New World: Regulatory Flexibility Key To AI Development, Stakeholders Say

About 130 stakeholders representing a broad spectrum of the health-care industry are asking the US FDA to consider taking a soft touch in any future guidance document addressing artificial intelligence and machine learning devices in order to keep up with developments in the field. Drug lobbyists have also asked the agency to develop guidance that reaches across centers to avoid future conflicts.

Rise Of The Machines: FDA Artificial Intelligence Guidance Is Coming

US FDA says as artificial intelligence and machine learning offer new opportunities to improve patient care, the agency hopes to encourage innovation by developing a draft guidance on the issue for sponsors. It also released a discussion paper outlining key issues it wants feedback on from industry and other key stakeholders.

Under New Rule, Sponsors Are Not Required To Submit Multiple Paper Copies To FDA

The US FDA has finalized a new rule that updates a slew of agency regulations so sponsors no longer have to submit multiple paper copies of premarket submission applications. The agency says the rule could save companies millions of dollars.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel